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ABSTRACT
While sociodemographic predictors of cervical cancer (CC) are well understood, predictors of
high-risk (HR) human papillomavirus (HPV) infection have not been fully elucidated. This study
explored the HR-HPV infection positivity in relation to sociodemographic, sexual behavior char-
acteristics and knowledge about HPV and CC prevention among women who visited the
Arkhangelsk clinical maternity hospital named after Samoylova, Russia. This cross-sectional
study was conducted in the city of Arkhangelsk, Northwest Russia. Women who consulted a
gynecologist for any reason between 1 January 2015 and 30 April 2015 were residents of
Arkhangelsk, 25–65 years of age were included. The Mann–Whitney and Pearson’s χ2 tests were
used. To determine the HR-HPV status, we used the Amplisens HPV-DNA test. We used a
questionnaire to collect the information on sociodemographic factors. Logistic regression was
applied. The prevalence of HR-HPV infection was 16.7% (n = 50). HR-HPV infection was more
prevalent in younger women, cohabiting, nulliparae, smokers, having had over three sexual
partners and early age of sexual debut. The odds of having a positive HR-HPV status increased
by 25% with an annual decrease in the age of sexual debut. Moreover women with one child or
more were less likely to have positive HR-HPV status.
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Human papillomavirus (HPV) is one of the most common
sexually transmitted infections worldwide. Most sexually
active individuals of both sexes will acquire it at some
points in their lives [1–3]. HPV genotypes are classified as
high-risk (HR) and low-risk based on their ability to cause
cervical cancer (CC) [4]. The presence and persistence of
high-risk human papillomavirus infection (HR-HPV) infec-
tion is a key etiological factor in the development of
carcinoma of the cervix and accounts for approximately
4.8% of all cancers [5]. CC accounts for 7.5% of all female
cancers [6]. It therefore significantly affects morbidity and
mortality risks worldwide [5]. CC has been termed “a
disease of disparity”. Within the European Union the high-
est CC mortality is seen in countries with the lowest
screening programmes participation rates [7]. High parti-
cipation in screening programmes employing the
Papanicolaou test (cytology-based) and subsequent treat-
ment of precancerous lesions has effectively reduced the
CC mortality [8,9]. Nevertheless, CC is considered a major
public health issue in Sweden, This country has the 9th
lowest CC mortality rate in the EU, high participation rate
and screening programme in place since 1967 [7,10,11]. In
addition, HPV is also associated with increased risk of
head and neck, vaginal, vulvar, penile and anal cancers
[11,12]. However, the prevalence of HPV in Russia remains
unknown or is controversial [13].
CC is the fourth most common female malignancy
worldwide with estimates of 528 000 of new cases and
266 000 deaths in 2012 [6]. Most of the cases arise from
countries with low-income or middle-income econo-
mies, where preventive resources are limited [14].
According to the report of International Agency for
Research on Cancer, CC is the second most frequent
cancer among women aged 15–44 years in Russia [15].
It is estimated that 64.5 million Russian women aged
15 years and older are at risk of developing this cancer,
and 15 342 women are diagnosed with CC, and 7 371
women die from the disease every year [15].
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Women positive for HR-HPV DNA have an increased
risk of developing CC. HPV infection is the most impor-
tant but not the only risk factor for CC. Many epidemio-
logical studies have so far focused on the role of co-
factors associated with the cancer development and
progression [1]. While sociodemographic predictors of
CC are well understood, those of HR-HPV infection have
not been. Epidemiological chain of infection involves
both women and men [16,17]. Both men and women at
the same time could be carriers without symptoms,
transmitters and the ones who experience active infec-
tion [18].
Predictors of HPV may differ from those of CC because
the development of the latter is influenced by many
variables, including co-factors involved in carcinogenesis
and adherence to screening guidelines [16,19,20]. Several
studies reported an association between HPV positivity
and lifetime number of sexual partners [16,19,21]. On the
other hand, the influence of age at sexual debut and
condom use on the risk of being HPV positive is question-
able [20,22,23]. Other potential risk factors for cervical HPV
infection include tobacco smoking [24], nulliparity [25,26],
and use of oral contraceptives [25]. Geographic and cul-
tural variations in the sexual behaviour of women and
their partners have also been reported to be strongly
associated with HPV acquisition [19,27].
Representative information about HR-HPV infection
in relation to different sociodemographic and sexual
behaviour characteristics have not been available in
Russia. Such data may be useful in designing effective
preventive public health strategies to reduce CC and
related mortality.
Aims
(i) To estimate prevalence of HR-HPV infection in
women who visited Arkhangelsk clinical maternity hos-
pital named after Samoylova in Arkhangelsk, Russia; (ii)
to identify sociodemographic characteristics and sexual
behaviour associated with HR-HPV status; and (iii) to
assess a possible association between the HR-HPV sta-
tus and knowledge about HPV and CC prevention.
Materials and methods
Study design, setting, participants and data
collection
This cross-sectional study was conducted between 1
January and 30 April 2015 in the city of Arkhangelsk,
which is the administrative centre of Arkhangelsk
County in Northwest Russia. In 2015 the population of
Arkhangelsk was 351 488, of whom 194 765 were
females, while 109 096 were in the 25–65 age
group [28].
Women who were residents of Arkhangelsk, aged 25
to 65 years and consulted a gynaecologist for any
reason at the Samoylova Clinical Maternity hospital
were recruited. Since there are no national guidelines
that regulate the cervical screening age in Russia, we
adopted that of the UK NHC Cervical Screening
Programme (NHSCSP). The latter recommends that rou-
tine screening be conducted during the 25–65 age
interval [29]. A sample size of 300 with an HPV preva-
lence of 10% was calculated to satisfy the condition (1 –
β) ≥ 0.80 at α = 0.05. The final analytical sample was
300, which constitutes 86% of women recruited.
All participants completed a questionnaire entitled
“HPV and CC Related Factors Questionnaire” which
sought information on the participants’ knowledge
about HPV and CC prevention and as described pre-
viously [30] included 14 questions pertaining to: socio-
demographic characteristics (age, education, marital
status, parity, smoking) and sexual behaviour character-
istics (age of sexual debut, history of sexually transmitted
infections, contraception, history of the papanicolaou
test (the Pap test) and related abnormal findings and
their management).
At enrolment, women underwent a pelvic examina-
tion with collection of cervical specimens for cervical
cytology and for HR-HPV DNA genotyping. The cervical
smears were collected with a cervical cytobrush and
were transported to the laboratory and stored in a buffer
solution. Liquid-based cytology (LBC) (SurePath
Technology; TruePath Imaging Inc, Burlington, NC) sam-
ples were sent to the central laboratory for cytological
diagnosis, HPV detection and genotyping (Central
Research Institute of Epidemiology “Rospotrebnadzor”,
Moscow, Russia). Pap smears were prepared and
reviewed by the study pathologist who was not aware
of the HPV results. Abnormalities were reported accord-
ing to the Bethesda System 2001 [31]. Smears were
classified as normal, atypical squamous cells of undeter-
mined significance (ASCUS), low-grade squamous intrae-
pithelial lesions (LSIL), high-grade squamous
intraepithelial lesions (HSIL) or carcinoma. Women with
ASCUS and negative HPV test were recommended to
repeat both tests in 6 months. Women with other abnor-
mal cytological findings and/or positive HPV test were
referred to colposcopy and histologic confirmation.
HPV positivity was determined using an HPV DNA
test (AmpliSens® HPV HCR screen-titre-FRT PCR kit,
InterLabService, Moscow, Russia), which is an in vitro
nucleic acid amplification test for qualitative and quan-
titative detection in biological materials of DNA of HPV
of high carcinogenic risk (HCR). This test is able to
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detect DNA of HR-HPV of the four phylogenetic groups,
namely A7 (HPV types: 18, 39, 45, and 59), and A9 (HPV
types: 16, 31, 33, 35, 52, and 58), A5 (HPV type 51) and
A6 (HPV type 56). The analytical sensitivity was 1 × 103
copies/ml. An endogenous internal control was present
in all our HPV kits, which allowed an assessment of the
control stages of PCR (DNA isolation and amplification)
and an evaluation of sample quality and storage ade-
quacies. When epithelial swab quality was not sufficient
(i.e. insufficient number of epithelial cells in the clinical
sample), the signal of β-globin gene was significantly
lower. This β-globin based Internal Control protocol
significantly reduces false negative results caused by a
poor clinical sample quality. Samples were considered
to be positive with an HPV-DNA threshold of 1pg/ml,
which is recommended by the USA Food and Drug
Administration (US FDA). Automated results were con-
firmed with blind manual readings undertaken by
experienced laboratory personnel.
Variables
For the analyses, women were grouped based on
their age (25–29, 30–39, ≥ 40), marital status (married,
cohabiting, or single including divorced and/or
widowed), parity (0, 1, or ≥ 2 deliveries), and educa-
tion (university level or less). Age at sexual debut (in
years) was used as a continuous variable, and the
number of lifetime sexual partners was recorded as
3 or less and more than 3. History of sexually trans-
mitted infections was categorised into ever-had or
never-had. Smoking was designated as yes or no
(ever and never smokers). Contraception was cate-
gorised into use of condoms (yes and no) and use
of combined oral contraceptive pill for over 5 years
(yes and no). Participants’ knowledge about HPV and
CC prevention was used as both a discrete variable
(number of correct answers from 0 to 14) and a
binary variable. We considered having at least 50%
of the questions answered correctly (7 out of 14) as a
sufficient level of knowledge, and less than 50% of
the questions answered correctly (6 or less out of the
14 questions) as a poor.
HR-HPV infection was used as a binary variable (being
positive or negative for any type of HR-HPV) and were
categorised into the four groups HR-HPV infection types
mentioned, as well a mixed group that included HR-HPV
types from both group A9 and group A7.
Data analyses
The proportion of HR-HPV types are described and
displayed graphically in Figure 1. Sexual debut and
number of correct answers were presented as the med-
ian with the first and third quartiles. All the other vari-
ables were shown as numbers and percentages.
Statistical comparison between women with and with-
out HR-HPV infection was carried out using the Mann–
Whitney U test for continuous variables and Pearson’s
χ2 test for categorical variables.
We used logistic regression analysis to estimate
possible associations between the HR-HPV status as
the outcome and age, parity, age at sexual debut
and number of sexual partners as predictors. We
tested for linear trends by entering ordinal variables
as continuous in the regression analyses. As we
aimed to explore risk factors that are causally related
to the outcome these predictors were chosen based
on the previous knowledge taking into account the
cross-sectional design of the study and excluding
potential mediators. Crude and adjusted odds ratios
(ORs) were calculated with 95% confidence intervals
(95% CIs). The value of p < 0.05 was considered to
be statistically significant. The statistical analyses
were carried out using SPSS version 24 (SPSS Inc.,
Chicago, IL, USA).
Ethical approval was obtained from the Research
Ethics Committee of the Northern State Medical
University of Arkhangelsk, Northwest Russia (Registered
Report Number 08/12–14 from 10.12.2014) and from the
Norwegian Regional Committee for Medical and Health
Research Ethics, Tromsø, Norway (Registered Report




Of the 300 women recruited and examined in the
study, 16.7% (n = 50) were positive for HR-HPV. The
most commonly detected HPV types were group A9
and then group A7 (Figure 1). Multiple infections
were detected in 14% (n = 7). Around 97%
(n = 292) of the study participants had no pathologi-
cal findings in the Pap smear, while 2% (n = 6) had
L-SIL and 0.7% (n = 2) were assigned as having
atypical squamous cell undetermined significance
(ASCUS) changes in the smear.
Associations between sociodemographic charac-
teristics, sexual behaviour and knowledge about
HPV and cervical cancer prevention and the high-
risk HPV infection
Women aged 25–29 years (p = 0.013), those cohabit-
ing (p = 0.011), being nulliparae (p = 0.009), smokers
(p = 0.011) and having more than three sexual partners
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(p = 0.034) were more prevalent to have positive HRH
PV status rather than negative (Table 1). Moreover,
women with a positive HR-HPV status had sexual
debut at earlier age than women with a negative HR-
HPV status (p = 0.001). The prevalence of positive and
negative HR-HPV infections did not differ in women
with different educational levels, those with previous
abortions, hormonal contraceptive use, condom use
and history of sexually transmitted infections (Table 1).
Regardless of their HR-HPV status, the study parti-
cipants answered correctly more frequently to the
following questions/statements: “The chance of get-
ting HPV increases with number of sexual partners”;
“What is the main hazard of HPV for female”; and
“HPV vaccine is most effective if given to individuals
who have never had sex” (Table 2). The statement
“Most HPV types can clear up on their own if left
untreated” was the most poorly answered. We found
no difference in the numbers of correct answers
between women with positive and negative HPV sta-
tus (Table 2). The prevalence of poor knowledge was
not significantly different for participants with posi-
tive and negative HPV status (28.0% versus 18.4%
p = 0.121, respectively).
Factors associated with positive HPV status
In the crude analyses, risk of being positive for HR-
HPV infection increased gradually with being younger
and with lower parity: p-values for linear were 0.012
and 0.007, respectively (Table 3). Odds of having
positive HR-HPV status increased with an increased
lifetime number of sexual partners and with a
younger age at sexual debut. After adjustment for
all variables presented in Table 3, associations with
age and the number of sexual partners were no
longer significant.
Discussion
To the best of our knowledge, this study is the first in
Russia to explore potential risk factors and knowledge
about HPV and CC prevention in relation to HR-HPV
infection. In addition to young age, a lifetime number
of more than 3 sexual partners, nulliparity, cohabiting,
smoking and having earlier age at sexual debut were
associated with HR-HPV status. The independent risk
factors for positive cervical HR-HPV infection among
women aged 25–65 years consulting gynaecologists in
the Samoylova Clinical Maternity hospital were early
age at sexual debut and nulliparity.
The observed prevalence of HR-HPV infection in our
study was 16.7%, which is higher than the worldwide
prevalence of HPV infection in women without cervical
abnormalities of 11–12% [5,32]. Higher prevalence rates
have been reported in the Caribbean (35.4%), sub-
Saharan African (24%) and Eastern European (21%),
while those reported for North America (4.7%) and
Western Asia (1.7%) were lower compared to our esti-
mate [5]. The estimates of HR-HPV prevalence vary
between the regions, and this could in part be due to
different ages of the study populations, use of different
methods of HPV detection, different screening
Figure 1. Distribution of the phylogenetic types of high-risk HPV in women who visited Arkhangelsk Clinical Maternity Hospital,
Russia (n = 50).
Footnote: Phylogenetic types of high-risk HPV (in per cent): A7 (HPV types 18, 39, 45, and 59); A9 (HPV types 16, 31, 33, 35, 52, and 58); and other:
A5 (HPV type 51) and A6 (HPV type 56).
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Table 1. Associations between sociodemographic and sexual behaviour characteristics and HPV status in women
who visited Arkhangelsk Clinical Maternity Hospital named after Samoylova, Russia.
HPV status, n (%)
Characteristics Negative n = 250 Positive n = 50 P-value
Age 0.031
25–29 58 (23.2) 20 (40)
30–39 123 (49.2) 22 (44)
≥ 40 69 (27.6) 8 (16)
Marital status 0.029
Married 145 (58) 21 (42)
Cohabitation 45 (18) 17 (34)
Single 60 (24) 12 (24)
Parity 0.018
0 44 (17.6) 17 (34)
1 103 (41.2) 20 (40)
≥ 2 103 (41.2) 13 (26)
Education 0.108
University 142 (56.8) 22 (44)
Other 109 (43.2) 28 (56)
Lifetime number of sexual partners 0.034
1–3 141 (56.4) 20 (40)
> 3 109 (43.6) 30 (60)
Abortion 0.570
Yes 129 (51.6) 28 (56)
No 121 (48.4) 22 (44)
Age at sexual debut, years 0.001
Me (Q1–Q3) 18 (17–19) 17 (16–18)
Condom use 0.836
Yes 129 (51.6) 25 (50)
No 121 (48.4) 25 (50)
Sexually transmitted infections 0.468
Never had 129 (55.6) 25 (50)
Ever had 111 (44.4) 25 (50)
Smoking status 0.011
Yes 27 (10.8) 12 (24.0)
No 223 (89.2) 38 (76.0)
The value of p < 0.05 was considered to be statistically significant.
Table 2. Associations between knowledge about HPV and cervical cancer prevention and HPV status in women who visited
Arkhangelsk Clinical Maternity Hospital named after Samoylova, Russia (n = 300).
Questions about HPV and cervical cancer prevention
HPV status, n (%)a P-value
Negative n = 250 Positive n = 50
1. Have you ever heard of HPV? 156 (62.4) 34 (68.0) 0.453
2. Most HPV types can cleared up on their own. 23 (9.2) 7 (14.0) 0.302
3. HPV is very common in women. 205 (82.0) 38 (76.0) 0.324
4. The chance of getting HPV increases with number of sexual partners. 187 (74.8) 37 (74.0) 0.905
5. What is the main hazard of HPV for female? 206 (82.4) 41 (82.0) 0.946
6. A person usually does not have symptoms when infected with HPV. 118 (47.2) 22 (44.0) 0.679
7. Most sexually active women will never get HPV during their life. 165 (66.0) 37 (74.0) 0.271
8. According to Russian legislation, how often should routine screening for cervical cancer be done? 151 (60.4) 27 (54.0) 0.400
9. Cytological smear (Pap test) can detect changes that can lead to cancer if left untreated. 164 (65.6) 35 (70.0) 0.548
10. HPV vaccine can prevent cervical cancer. 94 (37.6) 13 (26.0) 0.118
11. HPV vaccine is most effective if given to individuals who have never had sex. 219 (87.6) 43 (86.0) 0.756
12. Someone who has undergone HPV vaccination cannot develop cervical cancer. 199 (79.6) 39 (78.0) 0.799
13. Women who have undergone HPV vaccination do not need a Pap test later in their life. 26(10.4) 3 (6.0) 0.336
14. HPV can be passed on during vaginal sexual intercourse. 155 (62.0) 31 (62.0) 1.000
Numbers of correct answer, scores, Me (Q1–Q3)b 8 (7–10) 9 (6–10) 0.716
Level of knowledgec: 0.121
sufficient 204 (81.6) 36 (72.0)
poor 46 (18.4) 14 (28.0)
aNumber (%) of women who answered correctly for each of the 14 questions.
bMedian (first and third quartiles) number of correct answers (from 0 to 14).
cNumber (%) of women who had sufficient (from 7 to 14 correct answers to the 14 questions)
or insufficient (< 7 correct answers) knowledge about HPV and cervical cancer prevention.
The value of p < 0.05 was considered to be statistically significant.
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programme implemented or variation in study designs
and exposure to HPV risk factors [32].
The prevalence of HPV among women in Russia has
been poorly documented and is restricted primarily to
studies conducted in Saint-Petersburg, where HR-HPV
positivity of 13% (n = 107) has been reported [33]. A
cohort study of women at risks for HPV infection in
three independent states of the former Soviet Union
suggested an overall HPV prevalence of 33.4% [34].
Differences in the prevalence estimates within Russia
may be partly explained by the disparity in the study
populations. Age is one of the major determinants of
the HPV infection prevalence. In our study group,
younger aged women (age groups 25–29 and 30–39)
tended to have an HPV positive status more often than
those aged 40 years or older. These findings are in
accordance with other studies that show that HPV
infection steeply decreases with age [20,22]. In general,
the younger a population is, the higher the prevalence
of HPV infection. It has been suggested that most HR-
HPV infections in young women are transient and often
involve sexual contacts with new partners, and that
persistent infections occur in a small proportion of
women [20].
One possible explanation for our observation that
cohabiting is associated with HPV infection could be
that the time since last exposure to HPV is longer in
married women than in singles. Also sexual activity in
single people tends to be sporadic [35]. Nevertheless,
there is a growing prevalence of sex outside marriage,
and thus marriage status does not reliably safeguard
sexual-health status [35–37].
We found an association between HR-HPV infection
and reproductive factors. There was a negative linear
trend observed for parity. That is consistent with a
study of Munoz et al. [38] where parity was a protective
factor for positive HPV status. The latter could be
explained by prenatal hormonal changes in the trans-
formation zone that contribute to HPV resistance dur-
ing sexual intercourse [39]. Study from Colombia
showed that high parity increases the risk of squa-
mous-cell carcinoma of the cervix among HPV-positive
women [40].
Despite the relatively low smoking rate (13%) among
our study subjects, we found that positive HPV status
was associated with cigarette smoking. A recent study
from the Murmansk region of North-West Russia reports
that the prevalence of smoking among women was
25.2% during 2006–2011 [41]. Differences in the time
frame, age and education level between the study
populations might have contributed to the discrepancy.
Although smoking is associated with an increased risk
of CC [42], its effect on HPV infection is mixed. Poppe
et al. [43] found that smoking potentially increased the
risk of HPV infection through a local impairment of cell-
mediated immunity, although the magnitude of the
effect was small. While some studies report an
increased risk of HPV infection among smokers [22],
others found a reduced risk [44].
Our observation that age at sexual debut and num-
ber of lifetime sexual partners are associated with posi-
tive HPV status is consistent with previous studies [19–
22]. Age at sexual debut appears to have declined over
time [45]. Most young women and men become sexu-
ally active during their teenage years and generally do
so unsafely [35]. Little knowledge and lack of access to
contraceptive related services explain the low use and
high rates of ineffective use. Greenberg et al. [46] have
demonstrated that early age at first sexual intercourse
in a female population was associated with risky
Table 3. Risk factors for positive high-risk HPV status among women who visited Arkhangelsk Clinical Maternity Hospital named
after Samoylova, Russia (n = 300).
Crude Adjusted*
Variable OR 95% CI P for linear trend OR 95% CI P for linear trend
Age 0.012 0.437
25–29 1.00 Reference 1.00 Reference
30–39 0.52 0.26–1.02 0.67 0.32–1.42
≥ 40 0.33 0.14–0.82 0.72 0.26–1.98
Parity 0.007 0.035
0 1.00 Reference 1.00 Reference
1 0.50 0.24–1.05 0.47 0.21–1.03
≥ 2 0.33 0.15–0.73 0.38 0.16–0.93
Sexual partner
1–3 1.00 Reference 1.00 Reference
> 3 1.94 1.04–3.60 1.65 0.85–3.24
Sexual debut
Years 0.77 0.65–0.91 0.80 0.67–0.96
*Method – Enter, R2 = 0.117, x2 = 21.576, p = 0.001.
Homer–Lemeshow test: x2 = 8.5, p = 0.385.
The value of p < 0.05 was considered to be statistically significant.
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behaviours, such as multiple sexual partners, intrave-
nous drug-use, higher likelihood of having sexually
transmitted diseases. Others have demonstrated that
risky behaviours including multiple sexual partners
and frequency of vaginal intercourse are associated
with HPV infection, particularly by the high oncogenic
risk types. Of these, a positive association with the
number of sexual partners has most consistently been
reported [20–22]. Multiple lifetime sexual partners has
been shown to increase the risk of being HPV-DNA
positive [19,40]. However, women tend to underreport
the number of lifetime sexual partners [22,35,36].
Our findings indicate that condom use was not asso-
ciated with HPV status. Munoz et al. [22] showed that
condoms most likely prevent HPV infection, although
the evidence of their effectiveness against other sexu-
ally transmitted diseases is mixed. Manhart et al. [23] in
their meta-analyses showed that there was no consis-
tent evidence that condom use reduces the risk of
becoming HPV-DNA positive. Authors suggest that
while condoms may not prevent HPV infection, they
may protect against genital warts and CC [23].
Underestimation of the potential protective effect of
condom use is possible, as very few women used it
consistently [47,48].
Long-term use of oral contraceptives could be a
cofactor that increases the risk of cervical carcinoma
[25]. Previous studies indicate that compared to never-
users, patients who used oral contraceptives for less
than 5 years did not have an increased risk of CC
[49,50]. However its use for over 5 years resulted in
higher risks of CC [25,26]. Almost 30 years ago it was
hypothesised that oestrogen and other hormones are
capable of reactivating HPV or increase its viral expres-
sion [51,52]. However this relation is not likely to be
causal. Contraceptive users may generally differ from
nonusers in other aspects than sexual behaviour.
Despite the sufficient level of knowledge about HPV
and CC prevention among our study participants, it
yielded no apparent protection against positive HPV
status. Neither was there a difference with education
level. Women with sufficient level of knowledge about
HPV and CC prevention had the same positive HPV
status as those with a poor level. One possible explana-
tion could be that the mode of communication
between women and their healthcare providers was
that scientific information was shared in a matter-of-
fact manner, with no or little attention to a problem’s
complexity or the context of a patient’s understanding
of a health issue. It may well be necessary to re-con-
ceptualise the education of healthcare workers to
include a better understanding of STDs and HPV
infection.
There remains little doubt that women who were
positive for HPV can be distinguished from those who
were HPV negative by a number of characteristics in
their reproductive health, their sexual behaviour and
preferences. However, many of the sociodemographic
characteristic as well as variables used to measure sex-
ual behaviour are closely interrelated and could be
potential confounders and/or mediators in multivari-
able analysis. Moreover, total exposure to some of the
potential risk factors, such as for example marital status
and smoking, could not be measured properly due to
cross-sectional design of the study. In relation to this, it
was difficult to build a regression model that would be
the best to explore potential independent risk factors.
We found that age at sexual debut and parity, but not
age or the lifetime number of sexual partners were
independent predictors for cervical HR-HPV infection.
Limitations
Our study has several potential limitations related to
cross-sectional design. Our study used non-probabilistic
sampling and this is why it cannot be generalised.
Despite the fact that we excluded the younger age
group (< 25 years old), it has been shown that initiation
of screening at an early age can lead to an overestima-
tion of CC risk [53]. All survey data based on self-reports
are susceptible to bias. Sexual behaviour might suffer
more than other variables because of social desirability
bias — the tendency for participants to respond
according to social expectations of what is acceptable.
Our study’s cross-sectional design has the risk of report-
ing bias, particularly in the context of variables that
address aspects of sexual behaviour, such as age at
sexual debut and lifetime number of sexual partners.
Many surveys find that women tend to under-report
the number of sexual partners [35–37]. Thus selection
bias might have occurred in our study. It is possible that
study participants were more health conscious in terms
of HPV and CC than women in the general population.
The cross-sectional study design is limited in reveal-
ing a causal relationship between HR-HPV positivity and
selected sociodemographic and sexual characteristics. It
measures prevalence and does not reflect any temporal
influence. Moreover, changes in social attitudes may
have affected the results of the survey since what is
being captured could in part reflect a change in beha-
viour itself. Furthermore, our study results cannot be
generalised. We can extrapolate our data only to
women who have visited gynaecologists for any reason
in the Arkhangelsk Clinical Maternity Hospital named
after Samoylova.
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Conclusion
The observed prevalence of HR-HPV is comparable to
estimates mentioned in previous studies. We have
established that women in the HR-HPV positive group
differed from the HR-HPV negative group by age, mar-
ital status, parity, age at sexual debut, number of sexual
partners and cigarette smoking. Women with early age
at sexual debut and those nulliparous have had a
higher risk of having a positive HR-HPV status. Our
results reinforce the importance of sexual behaviour
educational programmes for women and healthcare
providers in the prevention of HR-HPV infections.
There is no universal approach or a single intervention
that would work everywhere, as regional and local
social contexts can contribute to risky sexual practices.
Surveys of cervical HPV prevalence and related risk
factors can help to increase general understanding
and provide a basis for the design and establishment
of educational programmes and their assessment.
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